Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-09-18 00:00:00 ET · period of report 2024-09-16 · accession 0001415889-24-023610 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-18 | 2024-09-16 | ELVN | Heyman Richard A. | Dir | S - Sale | $22.41 | -1,270 | 129.1K | -1.0% | -$28.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | S | D | 1,270 | $22.41 | 129,103 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $22.11 to $22.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |